NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Palatin Technologies, Inc. (PTN) Stock Analysis

Palatin Technologies, Inc. (PTN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PTN

$5.55

+$0.03 (+0.54%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PTN with… →

PTN Key Statistics

As of Oct 21, 2026
Trading
Open
$5.60
Previous Close
$5.52
Day's Range
5.43–5.85
52-Week Range
5.40–31.00
Volume
20.48K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.01
Valuation
Market Cap
$9.88M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.62
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.75
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.96
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$17.31M
Profit marginThe share of revenue left as profit after all costs and taxes.
−63.54%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.78M
1-Year Return
−13.55%
Dividend and dates
Avg Volume
65.57K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PTN closed at $5.55, −13.55% over 1 year.

Palatin Technologies, Inc. (PTN) has a market capitalization of $9.88M.

In fiscal 2025, PTN reported revenue of $0.00.

PTN Stock Return by Calendar Year

Palatin Technologies, Inc. (PTN) 10-year return: what $10,000 became

1 year
$10,000 $8,645
−13.55%
5 years
$10,000 $101
−98.99%
10 years
$10,000 $82
−99.18%

If you had invested $10,000 in Palatin Technologies, Inc. (PTN) 10 years ago, at the close on October 21, 2016, it would have been worth $82 at the close on October 21, 2026: −99.18% in total, −38.13% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−63.91%
2025−72.29%
2024−72.11%
2023+55.47%
2022−79.92%
2021−25.00%
2020−12.82%
2019+9.86%
2018−17.44%
2017+68.63%
2016 (partial year)−10.53%

As of October 21, 2026.

PTN Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$17.31M—
2024$4.49M−$29.74M−662.3%
2023$4.85M−$24.04M−495.2%
2022$1.47M−$36.20M−2,465.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00$0.00−$22.71M−$17.31M—
2024$4.49M$4.39M−$30.28M−$29.74M−662.3%
2023$4.85M$4.44M−$33.49M−$24.04M−495.2%
2022$1.47M$1.25M−$36.59M−$36.20M−2,465.1%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

PTN Valuation vs Biotechnology Median

Median of 608 stocks
MetricPTNBiotechnology medianvs median
P/S ratio0.7513.300.1x the median
Profit margin−63.54%−38.31%25.2 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Palatin Technologies, Inc. (PTN) at $9.88M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 25.

Over the past 52 weeks the price has ranged from $5.40 to $31.00. The most recent close on file for PTN is $5.55, dated October 21, 2026. That is +$0.03 (+0.54%) against the previous close. The latest close sits 2.78% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. Against the prior fiscal year total of $4.49M, that is a change of −100.00%. The same year closed with a net loss of $17.31M. Profit margin runs at −63.54%. That is 25.2 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −2.96.

Across the 4 fiscal years on file, revenue moves from $1.47M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.62. Measured against sales, the shares trade at 0.75 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −13.55%. Measured over 10 years, that is −38.13% a year compounded. Beta against the wider market is reported at −0.01. Daily returns over the trailing 10 years annualize to a volatility of 107.11%.

Growth & Income

No dividend is on file for PTN.

2026 is still running; the total return is −63.91% year to date. Across the complete calendar years on file, 2017 returned +68.63% and 2022 returned −79.92%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Palatin Technologies, Inc. (PTN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Palatin Technologies, Inc. PTN $9.88M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Palatin Technologies, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Palatin Technologies, Inc.

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases. licensing arrangements and other strategic transactions to advance and maximize the value of certain product candidates and program for the treatment of retinal diseases and with Altanispac Labs for PL9643 for the treatment of dry eye disease; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Princeton, New Jersey.

Visit website →